Compile Data Set for Download or QSAR
Report error Found 1801 Enz. Inhib. hit(s) with Target = 'MAP kinase-interacting serine/threonine-protein kinase 1'
TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263270(CHEMBL4086747)
Affinity DataIC50: 0.0840nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550562(8′-Methyl-6′-(thieno[2,3-d]pyrimidin-4...)
Affinity DataIC50: 0.100nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50573219(CHEMBL4879010)
Affinity DataIC50: 0.150nMAssay Description:Inhibition of MKN1 (unknown origin) in presence of ATP by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2022
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550512(US11311520, Example 6 | US11311520, Example 32 | 8...)
Affinity DataIC50: 0.300nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550561(8′-Methyl-6′-(7H-pyrrolo[2,3-d]pyrimid...)
Affinity DataIC50: 0.300nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550512(US11311520, Example 6 | US11311520, Example 32 | 8...)
Affinity DataIC50: 0.300nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM168214(US9669031, 207 6′-((6-aminopyrimidin-4-yl)am...)
Affinity DataIC50: 0.310nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550654(8′-Methyl-6′-(7H-pyrrolo[2,3-d]pyrimid...)
Affinity DataIC50: 0.400nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550702(8-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-...)
Affinity DataIC50: 0.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM168214(US9669031, 207 6′-((6-aminopyrimidin-4-yl)am...)
Affinity DataIC50: 0.510nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550534(6′-({6-[(3-Aminoazetidin-1-yl)carbonyl]thien...)
Affinity DataIC50: 0.600nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50500934(CHEMBL3800585)
Affinity DataEC50:  0.600nMAssay Description:Inhibition of MNK1/2 in human KMS11-luc cells assessed as inhibition of EIF4E phosphorylation at S209 after 3 hrs by quantitative electrochemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263254(CHEMBL4094975)
Affinity DataIC50: 0.620nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50263269(CHEMBL4076439)
Affinity DataIC50: 0.650nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550573(8′-methyl-6′-(9H-purin-6-ylamino)-2...)
Affinity DataIC50: 0.700nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550638(3,3,8-Trimethyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl...)
Affinity DataIC50: 0.700nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550596(US11311520, Example 90 | 4,4-Difluoro-8′-met...)
Affinity DataIC50: 0.700nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263269(CHEMBL4076439)
Affinity DataIC50: 0.790nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50635319(CHEMBL5558538)
Affinity DataIC50: 0.800nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50263254(CHEMBL4094975)
Affinity DataIC50: 0.880nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550634(4-Hydroxy-8′-methyl-6′-(7H-pyrrolo[2,3...)
Affinity DataIC50: 1nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50587869(CHEMBL5174006)
Affinity DataIC50: 1nMAssay Description:Inhibition of MNK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/18/2023
Entry Details
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50042938(CHEMBL3355002)
Affinity DataIC50: 1nMAssay Description:Inhibition of human full-length MKNK1 using biotin-Ahx-IKKRKLTRRKSLKG substrate by TR-FRET-based high ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2016
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50587868(CHEMBL5201681)
Affinity DataIC50: 1nMAssay Description:Inhibition of MNK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/18/2023
Entry Details
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50042936(CHEMBL3355000)
Affinity DataIC50: 1nMAssay Description:Inhibition of human full-length MKNK1 using biotin-Ahx-IKKRKLTRRKSLKG substrate by TR-FRET-based high ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2016
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1 [1-424](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227719(US9556181, 4 | US9556181, 16 | US9556181, 7 | 3-br...)
Affinity DataIC50: 1nMpH: 7.5Assay Description:TBDA recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accessio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2018
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1 [1-424](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227732(US9556181, 17 | US9556181, 18 | US9556181, 20 | US...)
Affinity DataIC50: 1nMpH: 7.5Assay Description:TBDA recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accessio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2018
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50573222(CHEMBL4869634)
Affinity DataIC50: 1nMAssay Description:Inhibition of wild type human full length MKN1 (M1 to L424) expressed in mammalian expression system by HTRF methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2022
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50573221(CHEMBL4859971)
Affinity DataIC50: 1nMAssay Description:Inhibition of MKN1 (unknown origin) in presence of ATP by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2022
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM333401(2-{[3-(Furo[2,3-c]pyridin-2-yl)imidazo[1,2-b]pyrid...)
Affinity DataIC50: 1nMAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2019
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50573222(CHEMBL4869634)
Affinity DataIC50: 1nMAssay Description:Inhibition of MKN1 (unknown origin) in presence of ATP by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2022
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM333402(2-{[3-(Furo[3,2-c]pyridin-2-yl)imidazo[1,2-b]pyrid...)
Affinity DataIC50: 1nMAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2019
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550684(8-methyl-6-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino...)
Affinity DataIC50: 1.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550704(8-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-...)
Affinity DataIC50: 1.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50573217(CHEMBL4876307)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of MKN1 (unknown origin) in presence of ATP by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2022
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550596(US11311520, Example 90 | 4,4-Difluoro-8′-met...)
Affinity DataIC50: 1.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50573217(CHEMBL4876307)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of MNK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2024
Entry Details
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50639441(CHEMBL5561655)
Affinity DataIC50: 1.10nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50573220(CHEMBL4857156)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of MKN1 (unknown origin) in presence of ATP by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2022
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550596(US11311520, Example 90 | 4,4-Difluoro-8′-met...)
Affinity DataIC50: 1.20nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50263255(CHEMBL4065802)
Affinity DataIC50: 1.40nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50500931(CHEMBL3797873)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of ERK2-activated full length wild type MNK1a (unknown origin) using biotin-SGSGKRREILSRRPSYR-NH2 as substrate after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50263264(CHEMBL4094080)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550530(8′-methyl-6′-(9H-purin-6-ylamino)-2...)
Affinity DataIC50: 1.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550580(6′-({6-[(3-Aminoazetidin-1-yl)carbonyl]thien...)
Affinity DataIC50: 1.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM168222(US9669031, 93 6-[(6-aminopyrimidin-4-yl)amino]-8-c...)
Affinity DataIC50: 1.60nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM168222(US9669031, 93 6-[(6-aminopyrimidin-4-yl)amino]-8-c...)
Affinity DataIC50: 1.80nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM550574(8′-methyl-6′-(1H-pyrazolo[3,4-d]pyrimi...)
Affinity DataIC50: 1.80nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50639452(CHEMBL5560868)
Affinity DataIC50: 1.80nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50635321(CHEMBL5505875)
Affinity DataIC50: 1.80nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
Displayed 1 to 50 (of 1801 total ) | Next | Last >>
Jump to: